StockDuty ← Dashboard Nov 05, 2026 03:02 AM ET
SignalCorporate

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates

XFOR topped Q3 revenue estimates despite reporting a loss.

What happened: X4 Pharmaceuticals ($XFOR) reported a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a $0.19 loss, and revenue of $2.88 million that beat the consensus estimate. Key numbers: Loss per share $0.16 vs. estimate $0.19; year-ago loss $0.69. Earnings surprise +15.79%. Why it matters: The report marks the fourth straight quarter the company surpassed consensus EPS estimates and the third time it topped revenue estimates in four quarters. The favorable estimate revisions trend ahead of the release translates into a Zacks Rank #2 (Buy). Market: +13.1% today ($258.38), +737.3% YTD, 0.7x vol — as of 00:45 UTC Verified: Q3_2026 (Nov 6) revenue $905.9M vs $905.9M est; next print ~Feb 5
X4 Pharmaceuticals ($XFOR) reported a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a $0.19 loss, and revenue of $2.88 million that beat the consensus estimate.
The report marks the fourth straight quarter the company surpassed consensus EPS estimates and the third time it topped revenue estimates in four quarters. The favorable estimate revisions trend ahead of the release translates into a Zacks Rank #2 (Buy). Market: +13.1% today ($258.38), +737.3% YTD, 0.7x vol — as of 00:45 UTC Verified: Q3_2026 (Nov 6) revenue $905.9M vs $905.9M est; next print ~Feb 5
Sources